Corbus Pharmaceuticals Holdings (CRBP) Non-Current Deffered Revenue (2015 - 2018)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Non-Current Deffered Revenue of $422337.0 for Q4 2018, down 57.32% year-over-year from $989550.0 in Q4 2017, and up 7.51% quarter-over-quarter from $392846.0 in Q3 2018.
Corbus Pharmaceuticals Holdings (CRBP) Non-Current Deffered Revenue (2015 - 2018) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $422337.0 for Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 57.32% year-over-year to $422337.0; the TTM figure through Dec 2018 stood at $422337.0 (down 57.32% YoY), while the FY2018 annual figure was $422337.0, down 57.32% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $422337.0, up from $392846.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $1.4 million in Q2 2018, with the low at $58206.0 in Q2 2017.
- The 4-year median for Non-Current Deffered Revenue is $338470.0 (2015), against an average of $480735.8.
- The sharpest annual moves came in 2016 and 2018: Non-Current Deffered Revenue sank 74.75% in 2016, then jumped 2224.34% in 2018.
- Corbus Pharmaceuticals Holdings' Non-Current Deffered Revenue stood at $260260.0 in 2015, then tumbled by 74.75% to $65724.0 in 2016, then surged by 1405.61% to $989550.0 in 2017, then tumbled by 57.32% to $422337.0 in 2018.
- Business Quant data shows CRBP's Non-Current Deffered Revenue at $422337.0 in Q4 2018, $392846.0 in Q3 2018, and $1.4 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 422,337.00 |
| Sep 30, 2018 | 392,846.00 |
| Jun 30, 2018 | 1.35 Mn |
| Mar 31, 2018 | 1.32 Mn |
| Dec 31, 2017 | 989,550.00 |
| Sep 30, 2017 | 102,561.00 |
| Jun 30, 2017 | 58,206.00 |
| Mar 31, 2017 | 62,182.00 |
| Dec 31, 2016 | 65,724.00 |
| Dec 31, 2015 | 260,260.00 |
| Sep 30, 2015 | 284,094.00 |
| Jun 30, 2015 | 454,748.00 |